Nanexa Q3 report: back to the clinic soon - ABG

Encouraging progress on BD, litigation, and clinical front


Opens for making NEX-18 superior to Vidaza


Co. sees good opportunities for securing needed funding


NEX-18 could have superior efficacy than Vidaza

The most relevant event during the quarter was the announcement of the selected compound and indication for the 3rd proprietary project NEX-22, which will be a long-acting formulation of liraglutide, a drug for type 2 diabetes. Nanexa also extended its collaboration with Applied materials and received GMP certification for its new production facility inaugurated in June. Furthermore, Nanexa and VitriVax reached an agreement on the patent infringement lawsuit, for which both companies filed a notice with the Court requesting it to be stayed while the parties work to finalize the agreed terms. Nanexa has recently also signed two new evaluation agreements, one with a global pharmaceutical company for the evaluation of PharmaShell in a long-acting injectable product for local administration (with an option to license), and another one (announced after the close of Q3), for a long-acting injectable intravitreal (eye) drug. In the report, Nanexa has confirmed that production of the NEX-20 investigational material has been completed for the upcoming Ph 1, due to start in Q4’22. Regarding the NEX-18 project, Nanexa stated that it will work pre-clinically to explore whether NEX-18 can achieve a superior effect vs. Vidaza, presumably delaying a return to the clinic.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/nanexa/Equity-research/2022/10/nanexa---q3-report-back-to-the-clinic-soon/